Vivani Medical (VANI) released preclinical data on weight loss effects for NPM-115
Vivani Medical (VANI) on Wednesday, unveiled preclinical findings regarding the weight loss effects of NPM-115, its miniature exenatide subdermal implant developed for chronic weight management, shedding light on its potential impact.
In a study involving high-fat diet-induced obese mice, NPM-115 demonstrated a remarkable weight reduction of approximately 20% compared to a control group with sham implants over a 28-day treatment period. The efficacy of NPM-115 rivaled that of Novo Nordisk A/S’s Ozempic/Wegovy injections (semaglutide), a popular weight loss treatment.
Both NPM-115 and semaglutide were administered at supratherapeutic doses to maximize their weight loss potential. Additionally, a separate study in healthy rats showcased the promising weight-reducing effects of NPM-119, a single-administration exenatide implant designed for type 2 diabetes treatment, with sustained release over 15 weeks.
NPM-115’s higher-dose formulation, akin to NPM-119, suggests enduring weight loss effects, affirming its potential in future clinical trials. Moreover, Vivani Medical disclosed plans for NPM-139, featuring semaglutide, as a once-yearly implant for chronic weight management, signaling a strategic shift towards obesity-focused implants.
The findings underscore the promising role of exenatide in weight management, hinting at a potential paradigm shift in obesity treatment. Notably, existing exenatide products face limitations in adherence and dosing, presenting an opportunity for innovative implant-based solutions in the field of weight management.
